TRYP THRAPEUTICS INC - TRYPF STOCK NEWS

Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) received a positive response from the FDA, allowing the company to proceed with its Phase 2a clinical trial for synthetic psilocybin targeting binge eating disorder. This follows a previous clinical hold announced on October 20, 2021, which has now been lifted after submission of an IND amendment on December 9, 2021. The trial will be conducted in partnership with the University of Florida, marking a significant step for Tryp after two FDA authorizations in 2021.

Tryp Therapeutics (CSE:TRYP, OTCQB:TRYPF) announced FDA approval for its Investigational New Drug (IND) application, allowing the company to commence a Phase 2a clinical trial for fibromyalgia using synthetic psilocybin formulation TRP-8802. Conducted in collaboration with the University of Michigan, this trial aims to address the needs of fibromyalgia patients through innovative psilocybin therapy and psychotherapy integration. Enrollment is set to begin in 2022, marking a crucial milestone for the company.

Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) reported its audited financial results for the fiscal year ending August 31, 2021. The company's total assets reached C$4.1 million, including C$3.7 million in cash, while net losses totaled C$8.3 million. Significant milestones in clinical development include FDA approval for a Phase 2a trial in fibromyalgia and partnerships with major universities for clinical studies. The company is advancing its proprietary psilocybin-based drug, TRP-8803, with innovative formulations aimed at improving patient experience.

Tryp Therapeutics (CSE:TRYP, OTCQB:TRYPF) announced that the FDA has completed its review of the company's IND application, allowing it to proceed with a Phase 2a clinical study for fibromyalgia. The trial, led by Dr. Kevin Boehnke from the University of Michigan, will evaluate the synthetic psilocybin formulation TRP-8802 in conjunction with psychotherapy. The study aims to enroll 20 fibromyalgia patients and examine various secondary endpoints associated with co-morbid conditions. Initiation of the trial is expected in 2022, marking a significant milestone for Tryp's clinical development.

Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) announced on November 18, 2021, that it has received feedback from the FDA regarding its IND application for a clinical study in overeating disorders. The FDA requested protocol modifications, which include focusing the initial phase 2a study on binge eating disorder and submitting an IND for a separate phase 2a study for hypothalamic obesity. Tryp plans to respond to the FDA within 10 days, expecting a reply within 30 days. The company aims to advance its psilocybin-based therapies for these specific conditions.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces plans to pursue five chronic pain indications with an estimated peak sales potential exceeding $12 billion. The company aims to launch two Phase 2a studies in 2021, followed by two more in early 2022. Currently, its market capitalization is under C$25 million. Tryp's PFN program focuses on synthetic psilocybin to treat neuropsychiatric disorders, with TRP-8802 targeting fibromyalgia affecting over five million in the U.S., and TRP-1001 for soft-tissue sarcoma. The initiatives aim to address unmet medical needs in the therapeutic landscape.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) has been featured in an editorial by NetworkNewsWire, highlighting the growing interest in psychedelic therapies for treating chronic diseases. The company is advancing its clinical programs, focusing on synthetic psilocybin for neuropsychiatric disorders, with its lead candidate TRP-8802 aimed at fibromyalgia, impacting over five million Americans. Tryp is also preparing a phase 2a clinical study for eating disorders in collaboration with the University of Florida and is developing TRP-1001 for soft-tissue sarcomas, potentially qualifying for orphan drug status.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announced a broadcast titled "Psychedelics — Not Just for Mental Health Anymore." The company's research into psilocybin's potential extends beyond depression to treat chronic pain and eating disorders. Tryp aims to develop synthetic psilocybin as a treatment option for neuropsychiatric disorders, with its lead candidate, TRP-8802, targeting fibromyalgia. Additionally, Tryp plans a phase 2a clinical study for eating disorders. The firm emphasizes its experienced management team in advancing drug candidates.

Tryp Therapeutics Inc. (CSE: TRYP, OTCQB: TRYPF) announced its inclusion in an editorial by NetworkNewsWire. The editorial discusses the expanding role of psychedelics beyond mental health, highlighting Tryp's efforts to create evidence-based therapies for chronic pain, particularly through its lead candidate TRP-8802 targeting fibromyalgia. The company is also preparing a phase 2a clinical study for eating disorders in collaboration with the University of Florida. Tryp's TRP-1001 is under development for soft-tissue sarcoma, aiming for orphan drug status due to its rarity.